VLP Therapeutics Receives FDA Clearance of Investigational New Drug Application and Initiates First Clinical Trial of VLPM01 Malaria Vaccine
Gaithersburg, MD – VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company’s VLPM01 malaria vaccine. The Phase
VLP Therapeutics Awarded $3.9 million Grant by Global Health Innovative Technology Fund for Further Development of Dengue Vaccine
December 12, 2018 Gaithersburg, MD - The Global Health Innovative Technology (GHIT) Fund has awarded VLP Therapeutics a $3.9 million grant to further develop a novel tetravalent dengue virus-like particle vaccine. “The GHIT Fund’s commitment
November 29, 2018 Dr. Wataru Akahata, CEO and Founder of VLP Therapeutics was Selected by the Government of Japan as a 2018 Researcher of Significant Contribution to Science Japan’s National Institute of Science and Technology
October 18, 2018 Gaithersburg, MD -- VLP Therapeutics announced the issuance of US Patent 10,098,943 titled, “Flavivirus virus-like particle” on October 16, 2018. This patent supports VLP Therapeutics’ Native Virus Modification virus-like particle platform on
Vaccines are one of the most important inventions in the past centuries. The successful vaccines save millions of lives by eradicating the epidemic and pandemic diseases. I left the research field and formed VLP Therapeutics because I am committed to developing the next generation vaccine technology to treat the diseases that currently lack effective treatment. We believe that our i-αVLP vaccine technology has a potential to create a breakthrough treatments and make significant contributions to the improvement of global public health.